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Abstract
Background: Introduction of pneumococcal conjugate vaccines (PCVs) of limited valency is justified in Africa by the high
burden of pneumococcal disease. Long-term beneficial effects of PCVs may be countered by serotype replacement. We
aimed to determine the impact of PCV-7 vaccination on pneumococcal carriage in rural Gambia.
Methods and Findings: A cluster-randomized (by village) trial of the impact of PCV-7 on pneumococcal nasopharyngeal
carriage was conducted in 21 Gambian villages between December 2003 to June 2008 (5,441 inhabitants in 2006). Analysis
was complemented with data obtained before vaccination. Because efficacy of PCV-9 in young Gambian children had been
shown, it was considered unethical not to give PCV-7 to young children in all of the study villages. PCV-7 was given to
children below 30 mo of age and to those born during the trial in all study villages. Villages were randomized (older children
and adults) to receive one dose of PCV-7 (11 vaccinated villages) or meningococcal serogroup C conjugate vaccine (10
control villages). Cross-sectional surveys (CSSs) to collect nasopharyngeal swabs were conducted before vaccination (2,094
samples in the baseline CSS), and 4–6, 12, and 22 mo after vaccination (1,168, 1,210, and 446 samples in CSS-1, -2, and -3,
respectively). A time trend analysis showed a marked fall in the prevalence of vaccine-type pneumococcal carriage in all
age groups following vaccination (from 23.7% and 26.8% in the baseline CSS to 7.1% and 8.5% in CSS-1, in vaccinated and
control villages, respectively). The prevalence of vaccine-type pneumococcal carriage was lower in vaccinated than in
control villages among older children (5 y to ,15 y of age) and adults ($15 y of age) at CSS-2 (odds ratio [OR]=0.15 [95%
CI 0.04–0.57] and OR=0.32 [95% CI 0.10–0.98], respectively) and at CSS-3 (OR=0.37 [95% CI 0.15–0.90] for older children,
and 0% versus 7.6% for adults in vaccinated and control villages, respectively). Differences in the prevalence of non-vaccine-
type pneumococcal carriage between vaccinated and control villages were small.
Conclusions: Vaccination of Gambian children reduced vaccine-type pneumococcal carriage across all age groups,
indicating a ‘‘herd effect’’ in non-vaccinated older children and adults. No significant serotype replacement was detected.
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The prevention of pneumococcal disease is a major interna-
tional public health priority, especially in children in developing
countries [1]. On the basis of a trial conducted in California in the
United States [2], the first licensed pneumococcal conjugate
vaccine (PCV), PCV-7, was introduced in the US in 2000. This
vaccine has been highly successful in reducing the incidence of
invasive pneumococcal disease (IPD) in both vaccinated children
and in the non-vaccinated older population [3,4]. This herd effect
has been attributed to reduced nasopharyngeal carriage of
pneumococci of vaccine type (VT) in vaccinated infants, resulting
in decreased transmission to contacts [3–6]. In the US, small
increases in the incidence of both IPD and carriage caused by
pneumococci of non-vaccine types (NVTs) have been detected, a
phenomenon termed serotype replacement [4,7–12]. In European
countries, the prevalence of serotypes included in PCV-7 is
generally lower than in the US, and the impact of PCV-7 has been
more heterogeneous, with less overall public health benefit as a
result of more marked serotype replacement [10–14].
Introduction of PCVs into the routine immunization programs
of sub-Saharan African countries is justified by the high
pneumococcal disease burden [1,15–19] and the evidence of
efficacy of PCVs provided by clinical trials [20,21]. However, the
ecology and epidemiology of pneumococcal carriage and IPD in
this region is different from that seen in the US or Europe. First,
rates of pneumococcal carriage in sub-Saharan Africa are among
the highest described [22–25] and result in high rates of
transmission [26]. Second, there is a wide variety of serotypes
associated with both carriage and invasive disease, and prevalence
of individual serotypes differs from those seen in developed
countries [15,22–28]. Third, vaccination in African countries is
usually a three-dose regimen given during infancy, without a
booster, as opposed to the booster-containing schedules widely
used in industrialized countries.
The factors that drive serotype replacement, which vary in
degree from community to community [29], are not fully
understood. It is likely that vaccination facilitates serotype
replacement by inducing a humoral and/or cellular immune
response that makes it more difficult for VT pneumococci to
colonize the nasopharynx, opening the way for colonization by
NVT pneumococci and, perhaps, by other bacteria. In countries
where PCV has been introduced into routine immunization
programs, immune pressure against VT pneumococci will increase
gradually as more vaccinated individuals enter the population.
Determining the consequence of this will require long-term
longitudinal studies. As an alternative, we have undertaken a
village-randomized trial in which the pneumococcal population of
some villages has been exposed to maximum immune pressure by
immunizing the whole population with PCV-7.
Methods
Study Population
Villages in the Sibanor area, Western Region, The Gambia,
were selected for the study as they are representative of rural areas
in The Gambia and are distant from the area where a PCV-9
vaccine trial had been undertaken a few years earlier [20].
Twenty-one of the 55 villages in the Sibanor area were selected
based on the criteria that they had a population ranging from 80
to 660 inhabitants and were separated from each other by a
distance of at least 3 km. The overall population of the selected
villages was 5,441 in June 2006. During the last trimester of 2006,
1,532 refugees from southern Senegal lived temporarily in these
villages. The prevalence of HIV infection among pregnant women
attending Sibanor Hospital, adjacent to the study area, between
2000 and 2001 was 3% [30] and is stable. The climate of The
Gambia is tropical with one short rainy season from June to
October. Other characteristics of the study population are
described elsewhere [23].
Study Preparation
Before the trial started, village meetings were held to discuss the
nature and objectives of the study with village elders and other
members of the study villages [23]. When village consent had been
obtained, the village was mapped and a full census taken and
updated annually. All residents of the 21 selected villages were
eligible for inclusion in the study, including those born during the
study period. Study participants gave individual informed consent;
parental consent was obtained for children up to 16 y of age.
The study was approved by the joint Medical Research Council
(MRC)/Gambia Government Ethics Committee and by the ethics
committee of the London School of Hygiene and Tropical
Medicine. The conduct of the trial was guided by a Data Safety
and Monitoring Board.
Trial Design
The protocol of the trial and CONSORT checklist are available
in Text S1 and Text S2, respectively.
A cluster-randomized (by village) controlled trial of PCV-7 was
conducted. PCV-7 was the study vaccine, and a meningococcal
serogroup C conjugate was the control vaccine. Blinding included
vaccine recipients and laboratory personnel. Study nurses were
aware of the nature of the vaccines given but played no other part
in the conduct of the trial.
Time trends within the vaccinated and control villages were
investigated using a before and after approach, measuring
pneumococcal carriage in PCV-7 vaccinated and control villages
before and after vaccination.
Pre-vaccination cross-sectional survey. Between 8
December 2003 and 19 May 2004, 2 y before vaccination
started, a baseline cross-sectional survey (CSS) was undertaken
in 21 villages in the Sibanor area. A nasopharyngeal swab (NPS)
was collected from a random selection of the village’s population
and cultured for pneumococci. Details of how this baseline study
was conducted and its findings have been reported previously [23].
The overall prevalence of pneumococcal carriage among children
and adults was approximately 70%. A random selection of the
NPSs collected in this baseline CSS has been used to provide a
population with a similar age distribution to the populations
investigated in the post-vaccination CSSs described below.
Sampling and culturing methods for the baseline and post-
vaccination CSSs did not differ.
Randomization. The number of residents in the study
villages varied substantially. Therefore, village randomization
was performed at the MRC laboratories at Fajara using several
steps. First, a random integer was chosen to select 11 or 10
intervention villages versus 10 or 11 control villages. Population
sizes in January 2006 for the 21 villages were stored in a Stata
program file (do file) for the village allocation scheme. One
thousand allocation-size-balanced schemes (difference between the
two groups of less than 10%) were created, and one was randomly
chosen.
Vaccination. Because the non-licensed PCV-9 vaccine
(including serotypes 1 and 5 in addition to the PCV-7 serotypes)
had already been shown to be effective in young children in a
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considered unethical not to give PCV-7 to young children in all of
the study villages. Therefore, all children in the trial aged between
2 and 30 mo at the start of the study, the age group covered by the
PCV-9 trial [20], received PCV-7, as did any child born during
the period of the study. Infants aged between 2 and 11 mo
received three doses of the vaccine given at monthly intervals, and
children aged between 12 and 30 mo received two doses with a 1-
mo gap between injections. Infants born during the study received
three doses of the vaccine given monthly at the ages of
approximately 2, 3, and 4 mo.
Village randomization was applied to individuals who were
above the age of 30 mo when vaccination started. On the basis of
their randomization group, individuals above the age of 30 mo
received either one dose of PCV-7 (Prevenar, Pfizer) (11
vaccinated villages) or one dose of a meningococcal serogroup C
conjugate vaccine (Meningitec, Pfizer) (10 control villages). The
meningococcal vaccine was given to ensure blinding and is not
expected to have had any effect on pneumococcal carriage.
PCV-7 vaccination started in 17 July 2006, and by 2 mo the
first round of vaccination had been completed (first dose given to
50%–75% of eligible individuals in vaccinated and control
villages). Meningococcal vaccine was unavailable for several
weeks, and hence meningococcal vaccination was delayed beyond
the intended date of administration. Individuals who moved into
the study villages during the study period were vaccinated and
managed following the standardized procedures of the trial,
including 1,532 Senegalese refugees who moved into 13 of the
study villages (869 in control and 633 in vaccinated villages) during
the last trimester of 2006. Following a census update, these
individuals were vaccinated and managed following the study
protocol. No serious adverse events that could be attributed to
PCV-7 were observed in children or adults.
Post-vaccination surveys. Approximately 4–6, 12, and
22 mo after vaccination, a NPS sample was collected from 1,200
randomly selected individuals during CSSs (post-vaccination CSS-
1 [15 November 2006–13 March 2007], CSS-2 [17 July–12
September 2007], and CSS-3 [8 July–1 September 2008],
respectively). It was originally planned that CSS-3 would be
conducted 24 mo after vaccination. However, a mass campaign by
the Gambian National Trachoma Elimination Programme
involving administration of one dose of azithromycin to all
individuals older than 6 mo of age except pregnant women started
at the time of the last study CSS in most study villages, meaning
that the results of this survey could not ultimately be used. Instead,
samples from a concurrent longitudinal survey in the same villages
taken 0 to 3 mo before the intended start of the final CSS (12
April–25 June 2008) were used to estimate the effects of
vaccination 2 y after the start of the trial. A maximum of one
sample per individual was included from this dataset, giving a total
of 446 samples that we called CSS-3. All these 446 samples were
collected before the azithromycin campaign started.
Sample Handling
NPSs were collected during all CSSs using a calcium alginate
swab, from the posterior wall of the nasopharynx, and immedi-
ately inoculated into vials containing skim-milk-tryptone-glucose-
glycerol transport medium, which were placed in a cold box before
transfer to the MRC Fajara laboratories (a distance of 90 km)
within 8 h of collection, in accordance with the World Health
Organization protocol for evaluation of pneumococcal carriage
[31]. Inoculated vials were stored at 270uC until they were tested
in batches by subculture onto gentamicin blood agar for selective
isolation of Streptococcus pneumoniae.
Laboratory Methods
10 ml of thawed, inoculated skim-milk-tryptone-glucose-glycerol
medium was plated onto gentamicin blood agar and incubated for
18–24 h at 35uCi n5 %C O 2. Pneumococcal identification was
based on colony morphology and conventional methods of
characterization (optochin susceptibility and bile solubility assays)
[23]. Serotyping was performed at MRC Fajara laboratories, with
capsular and factor typing sera (Statens Serum Institut), using a
modified latex agglutination assay [32]. Equivocal results were
confirmed by the Quellung reaction. Laboratory methods were
consistent for all CSSs.
Data Management and Statistical Analysis
Age groups were defined as follows: (i) young children:
individuals 2 to 5 y of age; (ii) older children: individuals 5 to
15 y of age; and (iii) adults: individuals aged 15 y and above.
Pneumococcal serotypes were grouped as follows: (i) VT: serotypes
included in PCV-7 (4, 6B, 9V, 14, 18C, 19F, and 23F) plus 6A,
which shows cross-protective immunity with serotype 6B; and (ii)
NVT: any other pneumococcal serotype including non-typable
pneumococcus. Individuals can carry more than one serotype, and
all serotypes were included in the analysis. The primary outcomes
of the study for each of the age groups were (i) the prevalence of
carriage of VT pneumococci and (ii) the prevalence of carriage of
NVT pneumococci.
The sample size was calculated so as to be able to detect a 50%
reduction in the prevalence of carriage of VT for each of the three
study age groups among individuals resident in PCV-7 vaccinated
villages compared to individuals from control villages, with 90%
power at a 5% significance level (from 30% to 15%). These
calculations resulted in an overall sample size of 1,200 individuals
per CSS. The study power for comparing study arms in CSS-3 was
compromised by the unanticipated trachoma elimination cam-
paign. In an ad hoc analysis, we also included comparison of
individual serotypes between vaccinated and control villages for
each CSS covering all study age groups. Because all children
under the age of 30 mo at enrollment or born during the study
received PCV-7 (in both vaccinated and control villages), the effect
of vaccination on carriage could not be measured among young
children by comparing vaccinated versus control villages.
However, the study protocol allowed the evaluation of the indirect
effect of vaccinating children on the rest of the population of the
control villages. Analysis of carriage used ‘‘person’’ as the unit of
analysis, whereas analysis of serotypes used ‘‘isolate’’ as the unit of
analysis.
Comparisons of median ages, village populations, and other
quantitative measures of household characteristics in vaccinat-
ed and control villages were made using Wilcoxon rank-sum
tests. Comparisons of sex, ethnic group distribution, and other
categorical variables were made using Chi-square tests. For
each of the CSSs, comparisons were made of carriage of VT
and NVT pneumococci in control versus vaccinated villages
using mixed effects logistic regression with village included as a
random effect to allow for the cluster randomized design.
Mixed effects logistic regression was used to compare carriage
in different CSSs within each study arm, treating CSS as a
categorical variable and adjusting for age as a continuous
variable. For individual serotypes, similar analyses were carried
out using fixed effects logistic regression and a clustered
sandwich variance estimator to allow for the clustered design.
The analyses were carried out using Stata 11 (StataCorp). p-
Values less than 0.05 were taken to indicate statistical
significance.
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Trial Profile
Twenty-one villages were randomized to one or the other of the
two study groups (Figure 1). Characteristics of the two groups of
villages (vaccinated and control) are shown in Table 1. Demo-
graphic and epidemiological characteristics of the villages were
similar, except for the distribution of ethnic groups (p,0.001); the
Mandinka ethnic group was overrepresented in the vaccinated
villages. Characteristics of the individuals included in each of the
study CSSs are shown in Table S1. The percentages of the
population that had been vaccinated by the time of each post-
vaccination CSS are shown in Figure 1 and Table S2. Vaccine
coverage with PCV-7 in the vaccinated villages ranged from 85%
to 92%. In the control communities, PCV-7 coverage in the post-
vaccination surveys increased from 33% (CSS-1) to 62% (CSS-3)
in young children, who represented 5% and 9% of the overall
population in this study arm, respectively. Additional information
regarding time since PCV-7 vaccination in the study villages
during each of the post-vaccination CSSs is shown in Table S3.
Although PCV-7 vaccination was conducted simultaneously in
vaccinated and control villages, NPS collection in CSS-1 was
performed slightly later in control than in vaccinated villages. In
CSS-1, half of the individuals were sampled within 177 d
(approximately 6 mo) after PCV-7 vaccination started in control
villages and within 125 d (approximately 4 mo) after PCV-7
vaccination started in vaccinated villages. Coverage with menin-
gococcal vaccine in older children and adults in control villages in
CSS-1 was low (Figure 1 and Table S2) and improved over the
CSSs, but this delay should not have any effect on the study
objectives.
Overall, 2,094 NPS samples were included in the pre-
vaccination CSS and 1,168, 1,210, and 446 NPS samples in
post-vaccination CSS-1, CSS-2, and CSS-3, respectively. Table 2
provides a summary of the number of samples collected per study
CSS and the median age and sex of sampled individuals in each
CSS. For CSS-3, children in the ‘‘young children’’ group were
older than in the previous CSS (median 4 versus 3 y, respectively,
p,0.001), and adults from the control communities were younger
than those in the vaccinated communities (median 26 versus 39 y,
respectively, p,0.001).
Prevalence of Pneumococcal Carriage
Pre-vaccination survey. The overall prevalence of
pneumococcal carriage in the pre-vaccination CSS was high
(71.1%) and decreased with age. The proportion of VT among
pneumococcal carriers also decreased with age. The prevalence
of pneumococcal carriage by age group and by future vaccine
arm are shown in Table 3. The overall prevalence was similar in
both study arms, but a slightly lower prevalence of VT carriage
was observed among villages where universal vaccination was
later introduced (not statistically significant for any of the
comparisons).
Comparisons of vaccinated and control villages in each of
the post-vaccination surveys. The overall prevalence of
pneumococcal carriage was similar in all post-vaccination CSSs
between vaccinated and control villages (Table 3; Figure 2).
The prevalence of carriage of VT pneumococci was lower in
vaccinated than in control villages in all post-vaccination CSSs for
all age groups, reaching statistical significance in CSS-2 and CSS-
3 (except for younger children) (Table 3; Figure 2).
The prevalence of carriage of NVT pneumococci was similar in
vaccinated and in control villages in all post-vaccination surveys,
except for a higher prevalence of NVT pneumococci among adults
in vaccinated communities during CSS-1 (odds ratio [OR]=1.50
[95% CI 1.03–2.18], p=0.035) (Table 3; Figure 2).
Time Trends within Trial Arms
The overall prevalence of pneumococcal carriage fell markedly
after vaccination and reached minimum levels in post-vaccination
CSS-2 in both study arms (Table 4; Figure 2) and in all age groups,
except adults in control villages, whose prevalence was lower in
CSS-1.
The decrease in the prevalence of VT carriage seen in both
vaccinated and control villages was statistically significant for all
age groups and any post-vaccination CSS when compared to the
pre-vaccination survey, with one exception in the control group
(see Table 4; Figure 2).
For NVT pneumococci, changes in the pattern of carriage
differed according to study age group (Table 4; Figure 2). Among
the youngest children, there was an increase in prevalence of NVT
pneumococci between baseline and CSS-1 that returned to
baseline levels in CSS-2 and CSS-3. Among older children, there
was a decrease in carriage of NVT pneumococci in CSS-2 in both
study arms, but carriage increased in CSS-3 to its former level.
Among adults, there was a significant decrease in carriage of NVT
between baseline and post-vaccination CSS-1 in both study arms,
and the final prevalence in CSS-3 was still lower than baseline
(OR=0.46 [95% CI 0.26–0.82], p=0.008, and OR=0.53 [95%
CI 0.31–0.92], p=0.024, for control and vaccinated villages,
respectively).
In the time trend analysis, the overall decrease between the pre-
vaccination CSS and CSS-1 was bigger for VT than for NVT in
both vaccinated (OR=0.24 [95% CI 0.17–0.33] for VT and
OR=0.58 [95% CI 0.47–0.72] for NVT) and control villages
(OR=0.23 [95% CI 0.16–0.33] for VT and OR=0.72 [95% CI
0.59–0.89] for NVT) (Table 4).
Individual Serotypes
The most prevalent serotypes in the pre-vaccination CSS
among VT pneumococci were serotypes 23F (n=86), 6A (n=84),
and 6B (n=80), and among NVT pneumococci, serotypes 3
(n=182), 11 (n=81), and 7C (n=52). During the post-vaccination
CSSs, serotype 3 remained the most prevalent among NVT
isolates, followed by serotype 11, except for CSS-3, when serotypes
11 and 19A were the most common. The most prevalent VT
serotypes in the post-vaccination surveys were serotypes 19F and
6A. Table 5 shows the prevalence of VT serotypes and the most
prevalent NVT serotypes for each CSS in vaccinated and control
villages. The prevalence of carriage of serotype 5 pneumococci
increased in vaccinated villages from 0% to 4.7%. Seven of the 11
serotype 5 isolates detected in CSS-3, were obtained from older
children (64%), and seven came from the same village.
Details of the time trends for individual serotypes within
vaccinated and control villages are shown in Table S4. Most of the
VT serotypes significantly decreased compared to the baseline
CSS in vaccinated and control villages. Decrease of serotype 6A
was less prominent in control villages. Of the most prevalent NVT
serotypes, serotype 3 and 7C decreased in vaccinated communi-
ties, and serotypes 5, 19A, and 23B significantly increased in
vaccinated communities in CSS-3.
Discussion
To anticipate the potential long-term effects of the introduction
of pneumococcal conjugate vaccination in sub-Saharan Africa, we
have conducted a novel randomized, controlled trial in which a
population of pneumococci was exposed to maximum immune
Impact of PCV Vaccination on Pneumococcal Carriage
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PCV-7. We measured the prevalence of pneumococcal carriage in
these villages before and on three occasions after vaccination, and
compared these findings with those obtained in control villages
where only young children had been vaccinated with PCV-7.
Time trends were investigated by comparing pneumococcal
carriage within both groups of villages before and after
vaccination.
By the time this study was ready to start, the results of the
Gambian PCV-9 trial had become available [20], showing a high
Figure 1. Trial profile. MCC, meningococcal polysaccharide C conjugate vaccine.
doi:10.1371/journal.pmed.1001107.g001
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so it was considered unethical to proceed with a trial in which all
children in this age group did not receive PCV, as had been
originally intended. This design modification weakened the ability
of the study to show the direct effect of vaccination on the
community through differences between vaccinated and control
villages, but serendipitously allowed demonstration of a potential
herd effect resulting from immunization of children in control
communities. Changes in the prevalence of carriage between the
before and after vaccination surveys need to be interpreted with
caution because of the potential influence of temporal trends
unrelated to vaccination. However, methods used for sampling
and isolation of pneumococci were consistent over the study
period, including pre- and post-vaccination surveys. Furthermore,
the investigators are not aware of any changes in the study villages
that could have affected risk factors for carriage during the
conduct of the study, apart from the administration of azithro-
mycin at the time of the last CSS, an event which has been
addressed in the analysis.
A time trend analysis showed a marked drop in the prevalence
of carriage of VT pneumococci among all age groups in
vaccinated and control villages following vaccination. The decline
in the prevalence of VT carriage in older children and adults in
the control villages strongly suggests a herd effect resulting from
vaccination of infants and toddlers in those villages. This effect was
apparent as early as 6 mo after vaccination and persisted for at
least the next 2 y. This finding is in line with results from a pre-
vaccination observational study conducted in the same villages
that suggested that transmission occurred mainly from young
children to older members of the family [26]. Although the study
villages were separated by at least 3 km, some mingling between
communities may have contributed to the herd effect observed in
the control villages, as some older children resident in these
villages attended school in neighboring villages. Because of the
high level of transmission of pneumococcal infection in Africa
[26], there have been concerns that induction of herd immunity
through vaccination of infants might be more difficult to achieve in
this continent than elsewhere. We have shown here, to our
knowledge for the first time in Africa, a herd effect on carriage of
VT pneumococci, which might be translated into herd protection
against IPD in adults, following routine immunization of infants
and young children, as has been observed in the US [4]. Our
findings are relevant for other countries in Africa contemplating
the introduction of PCVs where the pattern of pneumococcal
infection is similar to that in The Gambia. Whether a similar effect
will be observed in countries with a high prevalence of HIV (HIV-
infected adults are more susceptible to being carriers of pediatric
pneumococcal serotypes) remains unknown.
The prevalence of carriage of VT pneumococci was slightly
lower, but statistically significantly so, in individuals from
Table 1. A comparison of characteristics of the population residents at the start of the trial (17 July 2006) in the control and
vaccinated villages.
Characteristic Control Villages Vaccinated Villages p-Value
Village populations
Total 2,765 2,676
Median (range) 198 (140–528) 251 (69–634) p=0.622
Total number of babies born during the trial (17 July
2006–1 September 2008)
190 215 p=0.233
Age distribution
,30 m (%) 6.2 6.8
30 m to 59 m (%) 7.4 8.3
5yt o,15 y (%) 28.2 29.9
15 y to ,50 y (%) 45.7 41.7
$50 y (%) 12.4 13.3
Median (years) 18 16 p=0.372
Sex distribution
Male (%) 50.1 49.8
Female (%) 49.9 50.2 p=0.796
Median number of compounds (range) 13 (4–27) 11 (6–37) p=0.750
Median number of households per compound (range) 1 (1–9) 1 (1–17) p=0.246
Median distance from Sibanor main road (IQR) 3 (2–4) 4 (2–6) p=0.422
Median distance from the closest health center (IQR) 9.5 (5–12) 6 (3–13) p=0.447
Cooking fuel
Collect firewood (%) 95.3 91 p=0.041
Buy firewood (%) 1.8 10.1 p#0.001
Crop residues (%) 1.5 1.4 p=1.000
Charcoal (%) 1.8 1.2 p=0.519
Gas (%) 1.5 1.7 p=1.000
IQR, interquartile range.
doi:10.1371/journal.pmed.1001107.t001
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comparisons. Thus, vaccination of older children and adults with
PCV-7 had some additional effect in decreasing rates of carriage of
VT pneumococci, but this effect was not marked.
The prevalence of carriage of NVT pneumococci among
adults was lower in the post-vaccination surveys than in the pre-
vaccination survey in both control and vaccinated communities.
This decrease was not observed in other age groups in either
vaccinated or control villages, so this may have been a chance
finding. There was a significant gap between the time that the
pre-vaccination study was done and the first post-vaccination
survey, and it is possible that there may have been some change
in the pattern of carriage in the study villages during this time.
However, surveys undertaken in The Gambia over a period of
many years, including several conducted in the study area, have
consistently shown very high levels of carriage, and it is unlikely
that the overall level of carriage would have changed during this
period, although there could have been some changes in serotype
distribution [7,23,24,26,28,33]. ‘‘Up and down’’ trends in the
prevalence of different serotypes have been documented previ-
Table 3. Comparison of the prevalence of pneumococcal carriage of any pneumococcal serotype, VT serotypes, and NVT
serotypes between control and vaccinated villages in each CSS.
Serotypes Survey Age Group Prevalence of Carriage OR (95% CI) p-Value
Control Villages,
Percent (n/N)
Vaccinated Villages,
Percent (n/N)
Any type Pre-vaccination 2–,5 y 93.4% (99/106) 86.7% (98/113) 0.47 ( 0.14, 1.57) 0.218
5–,15 y 86.3% (271/314) 82.8% (346/418) 0.76 ( 0.49, 1.20) 0.241
$15 y 60.6% (320/528) 57.6% (354/615) 0.89 ( 0.64, 1.26) 0.518
CSS-1 2–,5 y 89.8% (53/59) 87.8% (79/90) 0.83 ( 0.27, 2.52) 0.737
5–,15 y 63.0% (131/208) 61.3% (125/204) 0.96 ( 0.60, 1.53) 0.872
$15 y 24.2% (72/298) 31.1% (96/309) 1.41 ( 0.99, 2.02) 0.058
CSS-2 2–,5 y 64.3% (45/70) 58.0% (40/69) 0.77 ( 0.39, 1.52) 0.445
5–,15 y 52.5% (115/219) 41.4% (84/203) 0.64 ( 0.37, 1.10) 0.107
$15 y 29.1% (97/333) 23.1% (73/316) 0.76 ( 0.49, 1.19) 0.230
CSS-3 2–,5 y 78.9% (30/38) 76.7% (23/30) 0.71 ( 0.11, 4.49) 0.717
5–,15 y 66.7% (72/108) 68.9% (91/132) 1.16 ( 0.62, 2.18) 0.645
$15 y 34.8% (23/66) 29.2% (21/72) 0.77 ( 0.35, 1.70) 0.519
VT Pre-vaccination 2–,5 y 53.8% (57/106) 50.4% (57/113) 0.88 ( 0.51, 1.52) 0.640
5–,15 y 34.7% (109/314) 28.0% (117/418) 0.72 ( 0.47, 1.11) 0.138
$15 y 16.7% (88/528) 15.9% (98/615) 0.95 ( 0.69, 1.30) 0.738
CSS-1 2–,5 y 28.8% (17/59) 20.0% (18/90) 0.61 ( 0.25, 1.48) 0.277
5–,15 y 8.7% (18/208) 5.9% (12/204) 0.67 ( 0.30, 1.47) 0.317
$15 y 4.4% (13/298) 4.2% (13/309) 0.96 ( 0.44, 2.11) 0.925
CSS-2 2–,5 y 27.1% (19/70) 21.7% (15/69) 0.88 ( 0.32, 2.42) 0.801
5–,15 y 8.7% (19/219) 1.5% (3/203) 0.15 ( 0.04, 0.57) 0.005
$15 y 3.9% (13/333) 1.3% (4/316) 0.32 ( 0.10, 0.98) 0.046
CSS-3 2–,5 y 23.7% (9/38) 13.3% (4/30) 0.50 ( 0.14, 1.80) 0.287
5–,15 y 14.8% (16/108) 6.1% (8/132) 0.37 ( 0.15, 0.90) 0.029
$15 y 7.6% (5/66) 0.0% (0/72) 0.00 — —
NVT Pre-vaccination 2–,5 y 50.9% (54/106) 54.0% (61/113) 1.16 ( 0.62, 2.16) 0.643
5–,15 y 58.9% (185/314) 60.8% (254/418) 1.08 ( 0.80, 1.46) 0.613
$15 y 41.7% (220/528) 41.0% (252/615) 0.97 ( 0.76, 1.24) 0.815
CSS-1 2–,5 y 66.1% (39/59) 67.8% (61/90) 1.09 ( 0.52, 2.26) 0.823
5–,15 y 56.3% (117/208) 57.4% (117/204) 1.05 ( 0.71, 1.54) 0.821
$15 y 20.5% (61/298) 27.8% (86/309) 1.50 ( 1.03, 2.18) 0.035
CSS-2 2–,5 y 40.0% (28/70) 42.0% (29/69) 1.09 ( 0.55, 2.14) 0.808
5–,15 y 44.7% (98/219) 40.4% (82/203) 0.86 ( 0.50, 1.47) 0.587
$15 y 25.8% (86/333) 22.2% (70/316) 0.84 ( 0.54, 1.30) 0.434
CSS-3 2–,5 y 60.5% (23/38) 63.3% (19/30) 1.02 ( 0.24, 4.26) 0.982
5–,15 y 52.8% (57/108) 62.9% (83/132) 1.66 ( 0.86, 3.19) 0.129
$15 y 30.3% (20/66) 29.2% (21/72) 0.96 ( 0.43, 2.13) 0.924
Surveys were pre-vaccination and 4–6 mo (CSS-1), 12 mo (CSS-2), and 22 mo (CSS-3) post-vaccination.
doi:10.1371/journal.pmed.1001107.t003
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includes a nonspecific effect on health produced by the
intervention, but such an effect should have been observed in
all age groups. Still, the observed decrease of NVT pneumococci
prevalence from the pre-vaccination CSS to post-vaccination
CSS-1 was significantly lower than the decrease of VT
pneumococci prevalence observed for these two CSSs in both
vaccinated and control communities.
The absence of a significant increase in the prevalence of
carriage of NVT pneumococci in any age group, and the limited
differences between control and vaccinated villages, are surprising,
as many previous studies [8,9,12], including some conducted in
The Gambia [7,34], have shown a marked increase in the
prevalence of carriage of NVT pneumococci after vaccination.
These previous carriage studies conducted in The Gambia focused
on infants and younger children [7,34], an age group not sampled
in our study. Lack of an increase in NVT pneumococci prevalence
has previously been documented in a carriage study of household
contacts among Native Americans whose children participated in
a PCV-7 vaccine trial [35]. The investigators observed no increase
in carriage of NVT pneumococci among older children and adults
within households of children vaccinated with PCV-7, although a
reduction in carriage of VT pneumococci was found in the adult
age group. An increase in carriage of NVT pneumococci was
found only in non-vaccinated household members ,5 y of age
from households with PCV-7 vaccinees. Encouragingly, vaccina-
tion of older children and adults in our study did not add selection
pressure towards an overall increase in carriage of NVT
pneumococci.
We have also observed in our study a decrease of the overall
pneumococcal carriage in the post-vaccination CSSs compared to
the pre-vaccination CSS. Because there is little serotype
replacement, PCV introduction might also have had an effect on
the overall prevalence of pneumococcal carriage at least up to 2 y
after vaccination. Pneumococcal prevalence reached its lowest
levels in the post-vaccination CSS-2. As mentioned above, secular
trends or the health effect of the intervention could partly explain
such results.
An increase in carriage of serotype 5 pneumococci seen in
vaccinated villages in CSS-3 was due largely to an outbreak in one
village and may have been a chance finding unrelated to
vaccination, an event similar to one observed in the study
community before any intervention was performed [26]. However,
the possibility of an association with PCV vaccination is of concern
as this serotype, along with serotype 1, is a major cause of IPD in
The Gambia [36] and elsewhere in Africa [15,22,27]. Both
serotype 5 and serotype 1 pneumococci also have the potential to
cause epidemics [37–39]. An increase in the prevalence of carriage
Figure 2. Prevalence of pneumococcal carriage of VT, NVT, and any serotype, in CSSs before and after vaccination of infants and
young children, stratified by age group and study arm. Solid lines indicate control villages; dashed lines indicate vaccinated villages.
doi:10.1371/journal.pmed.1001107.g002
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3 in the vaccinated villages (shown in both the arm comparison
and the time trend analysis), probably driven by young children.
An increase in carriage of serotype 19A after PCV vaccination has
been documented previously in The Gambia [7] and elsewhere
[8,9,11,12]. An increase has also been widely documented for IPD
caused by this serotype [4,10,11], demonstrating lack of cross-
protection of PCV-7 for serotype 19A. Serotype 6A was still
present in all post-vaccination surveys but with lower prevalence in
each of the post-vaccination CSSs compared to the pre-
vaccination survey in both vaccinated and control communities,
suggesting the expected vaccine protective effect in carriage, and
potentially on IPD, a finding that justifies inclusion of this serotype
in the VT group. However, the 6A decrease was statistically
Table 5. Pneumococcal carriage of individual serotypes in the pre-vaccination and post-vaccination surveys in control and
vaccinated villages.
Individual
Serotypes Pre-Vaccination CSS Post-Vaccination Surveys
CSS-1 CSS-2 CSS-3
Control
Villages
(n=948),
n(%)
Vaccinated
Villages
(n=1,146),
n (%)
OR
(95% CI)
Control
Villages
(n=565),
n (%)
Vaccinated
Villages
(n=603),
n (%)
OR
(95% CI)
Control
Villages
(n=622),
n (%)
Vaccinated
Villages
(n=588),
n (%)
OR
(95% CI)
Control
Villages
(n=212),
n (%)
Vaccinated
Villages
(n=234),
n (%)
OR
(95% CI)
VT
4 25(2.6) 49(4.3) 1.65
(0.69, 3.91)
3(0.5) 0(0.0) NC 1(0.2) 0(0.0) NC 3(1.4) 0(0.0) NC
6B 40(4.2) 40(3.5) 0.82
(0.47, 1.43)
7(1.2) 8(1.3) 1.07
(0.49, 2.37)
10(1.6) 6(1.0) 0.63
(0.13, 3.02)
5(2.4) 1(0.4) 0.18(0.02, 1.51)
9V 40(4.3) 29(2.5) 0.57
(0.29, 1.12)
1(0.2%) 4(0.7) 3.77
(0.33, 42.52)
3(0.5) 0(0.0) — 1(0.5) 2(0.9) 1.82(0.15,
22.70)
14 21(2.2) 15(1.3) 0.59
(0.20, 1.76)
7(1.2%) 2(0.3) 0.27
(0.03, 2.32)
1(0.2) 1(0.2) 1.06
(0.07,
15.77)
1(0.5) 0(0.0) —
18C 30(3.2) 24(2.1) 0.65
(0.30, 1.41)
2(0.4%) 1(0.2) 0.47
(0.04, 4.89)
4(0.6) 0(0.0) — 5(2.4) 0(0.0) —
19F 33(3.5) 37(3.2) 0.93
(0.46, 1.84)
12(2.1) 8(1.3) 0.62
(0.18, 2.13)
8(1.3) 5(0.9) 0.66
(0.16, 2.79)
3(1.4) 5(2.1) 1.52(0.40, 5.76)
23F 52(5.5) 34(3.0) 0.53
(0.28, 1.01)
7(1.2) 6(1.0) 0.80
(0.26, 2.49)
11(1.8) 5(0.9) 0.48
(0.17, 1.31)
7(3.3) 0(0.0) —
6A 26(2.7) 58(5.1) 1.89
(1.00, 3.57)
9(1.6) 16(2.7) 1.68
(0.76, 3.72)
13(2.1) 6(1.0) 0.48
(0.16, 1.44)
6(2.8) 4(1.7) 0.60(0.18, 1.96)
NVT
a
1 4(0.4) 4(0.3) 0.83
(0.12, 5.59)
3(0.5) 0(0.0) — 4(0.6) 4(0.7) 1.06
(0.32, 3.50)
0(0.0) 2(0.9) —
5 6(0.6) 5(0.1) 0.14
(0.01, 1.31)
5(0.9) 1(0.2) 0.19
(0.02, 1.98)
0(0.0) 0(0.0) — 0(0.0) 11(4.7) —
b
3 76(8.0) 106(9.2) 1.17
(0.76, 1.81)
27(4.8) 19(3.2) 0.65
(0.30, 1.38)
36(5.8) 14(2.4) 0.40
(0.22, 0.73)
8(3.8) 8(3.4) NC
7C 10(1.1) 42(3.7) 3.57
(1.33, 9.54)
2(0.4) 0(0.0) NC 2(0.3) 2(0.3) NC 1(0.5) 0(0.0) NC
11 37(3.9) 44(3.8) 0.98
(0.50, 1.95)
10(1.8) 20(3.3) 1.90
(0.68, 5.33)
17(2.7) 13(2.2) 0.80
(0.27, 2.36)
9(4.2) 13(5.6) NC
15B 15(1.6) 23(2.0) 1.27
(0.37, 4.35)
7(1.2) 10(1.7) NC 9(1.4) 4(0.7) NC 7(3.3) 5(2.1) NC
19A 27(2.8) 20(1.7) 0.61
(0.30, 1.22)
3 (0.5) 8 (1.3) 2.52
(0.85, 7.44)
11(1.8) 3(0.7) 0.28
(0.06, 1.47)
6(2.8) 15(6.4) 2.35
c (0.73,
7.62)
23B 8(0.8) 2(0.2) 0.21
(0.04, 0.98)
6(1.1) 2(0.3) 0.31
(0.05, 1.88)
0(0) 3(0.5) — 1(0.5) 8(3.4) 7.47
c (1.09,
51.16)
34 14(1.5) 30(2.6) 1.79
(0.75, 4.31)
15(2.7) 21(3.5) 1.32
(0.34, 5.11)
11(1.8) 9(1.5) NC 8(3.8) 3(1.3) NC
VT includes the seven serotypes included in the vaccine and serotype 6A. NVT includes all other pneumococcal serotypes. All age groups are combined in this table.
aOnly those serotypes that were isolated in more than 3% of the samples in at least one group have been included. ORs were calculated only for serotypes with at least
15 isolates in one group.
bp-Value for this increase when considering risk difference and allowing clustering by village is p=0.151; 63.6% of the isolates (7/11) were detected in the same village.
cThe increase of prevalence in the vaccinated group during CSS-3 was led by an increase in young children. From the 30 samples collected in the vaccinated arm among
children 2 y to ,5 y of age, 16.7% (n=5) were isolate 19A and 10% (n=3) were isolate 23B.
NC, not calculated.
doi:10.1371/journal.pmed.1001107.t005
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the most prevalent NVT serotype detected both before and after
vaccination in this study, and serotype 19A was shown to be the
most common at some point after vaccination. Both of these
serotypes and serotype 6A are contained in the PCV-13, which has
been shown to be immunogenic in infants, with potential
protective effect against serotype-specific IPD [40–42]. PCV-13
has recently replaced PCV-7 in routine childhood immunization
programs in The Gambia and would be expected to provide
coverage of these serotypes.
This study faced an additional challenge. The last post-
vaccination survey was disrupted by the administration of
azithromycin to individuals in several study villages as part of a
national trachoma elimination program that had not been
envisaged when the carriage study was planned. To avoid any
direct or indirect effect resulting from this treatment, CSS-3
analyses include only a third of the target number of samples, all
collected before treatment started in the area, and therefore, this
survey lacked statistical power for comparison of vaccinated versus
control villages.
Despite the challenges and limitations of this study, the main
findings are robust and very encouraging. Vaccination of young
Gambian children reduced carriage of VT pneumococci in
vaccinated children but also in vaccinated and non-vaccinated
older children and adults, revealing to our knowledge for the first
time in Africa a potential herd effect from vaccination of young
children. The immunological pressure induced by vaccinating
whole communities did not lead to a community-wide increase in
carriage of NVT pneumococci during a 2-y period after
vaccination. Further long-term follow-up carriage studies in this
community are planned.
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Background. The prevention of pneumococcal disease,
especially in children in developing countries, is a major
international public health priority. Despite all the
international attention on the UN’s Millennium
Development Goal 4—to reduce deaths in children under
five years by two-thirds between 1990 and 2015—
pneumonia, sepsis, and meningitis together compose more
than 25% of the 10 million deaths occurring in children less
than five years of age. Streptococcus pneumoniae is a leading
bacterial cause of these diseases, and the World Health
Organization estimates that approximately 800,000 children
die each year of invasive pneumococcal disease.
Pneumococcal conjugate vaccines are currently available
and protect against the serotypes that most commonly
cause invasive pneumococcal disease in young children in
North America and Europe. Such vaccines have been highly
successful in reducing the incidence of invasive pneumo-
coccal disease in both vaccinated children and in the non-
vaccinated older population by reducing nasopharyngeal
carriage (presence of pneumococcal bacteria in the back of
the nose) in vaccinated infants, resulting in decreased
transmission to contacts—the so-called herd effect. Howev-
er, few countries with the highest burden of invasive
pneumococcal disease, especially those in sub-Saharan
Africa, have introduced the vaccine into their national
immunization programs.
Why Was This Study Done? The features of
pneumococcal nasopharyngeal carriage and invasive
pneumococcal disease in sub-Saharan Africa are different
than in other regions. Therefore, careful evaluation of the
immune effects of vaccination requires long-term,
longitudinal studies. As an alternative to such long-term
observational studies, and to anticipate the potential long-
term effects of the introduction of pneumococcal conjugate
vaccination in sub-Saharan Africa, the researchers conducted
a cluster-randomized (by village) trial in The Gambia in which
the whole populations of some villages were immunized
with the vaccine PCV-7, and other villages received a control.
What Did the Researchers Do and Find? With full
consent from communities, the researchers randomized 21
similar villages in a rural region of western Gambia to receive
pneumococcal conjugate vaccine or a control—
meningococcal serogroup C conjugated vaccine, which is
unlikely to affect pneumococcal carriage rates. For ethical
reasons, the researchers only randomized residents aged
over 30 months—all young infants received PCV-7, as a
similar vaccine had already been shown to be effective in
young infants. Before immunization began, the researchers
took nasopharyngeal swabs from a random selection of
village residents to determine the baseline pneumococcal
carriage rates of both the serotypes of pneumococci covered
by the vaccine (vaccine types, VTs) and the serotypes of
pneumococci not covered in the vaccine (non-vaccine types,
NVTs). The researchers then took nasopharyngeal swabs
from a random sample of 1,200 of village residents in both
groups of villages in cross-sectional surveys at 4–6, 12, and
22 months after vaccination. Villagers and laboratory staff
were unaware of which vaccine was which (that is, they were
blinded).
Before immunization, the overall prevalence of pneumococ-
cal carriage in both groups was high, at 71.1%, and
decreased with age. After vaccination, the overall prevalence
of pneumococcal carriage in all three surveys was similar
between vaccinated and control villages, showing a marked
fall. However, the prevalence of carriage of VT pneumococci
was significantly lower in vaccinated than in control villages
in all surveys for all age groups. The prevalence of carriage of
NVT pneumococci was similar in vaccinated and in control
villages, except for a slightly higher prevalence of NVT
pneumococci among vaccinated communities in adults at 4–
6 months after vaccination. The researchers also found that
the overall prevalence of pneumococcal carriage fell
markedly after vaccination and reached minimum levels at
12 months in both study arms and in all age groups.
What Do These Findings Mean? These findings show
that vaccination of young Gambian children reduced
carriage of VT pneumococci in vaccinated children but also
in vaccinated and non-vaccinated older children and adults,
revealing a potential herd effect from vaccination of young
children. Furthermore, the immunological pressure induced
by vaccinating whole communities did not lead to a
community-wide increase in carriage of NVT pneumococci
during a two-year period after vaccination. The researchers
plan to conduct more long-term follow-up studies to
determine nasopharyngeal carriage in these communities.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001107.
N The World Health Organization has information about
pneumococcus
N The US Centers for Disease Control and Prevention
provides information about pneumococcal conjugate
vaccination
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